41,322 Shares in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Acquired by ExodusPoint Capital Management LP

ExodusPoint Capital Management LP purchased a new stake in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 41,322 shares of the biopharmaceutical company’s stock, valued at approximately $42,000.

Several other large investors have also recently modified their holdings of the business. E Fund Management Co. Ltd. bought a new position in Sangamo Therapeutics during the 4th quarter worth $25,000. JPMorgan Chase & Co. raised its position in shares of Sangamo Therapeutics by 679.5% during the fourth quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 21,793 shares during the last quarter. PNC Financial Services Group Inc. increased its position in Sangamo Therapeutics by 2,319.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 26,078 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 25,000 shares during the period. SBI Securities Co. Ltd. bought a new position in Sangamo Therapeutics during the 4th quarter worth approximately $28,000. Finally, Shelton Wealth Management LLC acquired a new position in shares of Sangamo Therapeutics in the 4th quarter worth approximately $29,000. Institutional investors own 56.93% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on SGMO. Royal Bank of Canada reissued a “sector perform” rating and set a $2.00 target price on shares of Sangamo Therapeutics in a research note on Tuesday, March 18th. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Sangamo Therapeutics in a research report on Monday, April 7th. StockNews.com lowered Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, December 24th. Truist Financial lowered their target price on Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating for the company in a report on Thursday, January 23rd. Finally, Jefferies Financial Group cut their price target on Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating on the stock in a report on Tuesday, December 31st. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, Sangamo Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $5.17.

Sangamo Therapeutics Stock Up 4.5 %

Shares of SGMO opened at $0.75 on Tuesday. The business’s fifty day moving average is $0.91 and its 200 day moving average is $1.39. Sangamo Therapeutics, Inc. has a 12-month low of $0.30 and a 12-month high of $3.18. The stock has a market cap of $168.64 million, a P/E ratio of -1.00 and a beta of 1.57.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings data on Monday, March 17th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. The business had revenue of $7.55 million for the quarter, compared to analyst estimates of $11.70 million. On average, analysts expect that Sangamo Therapeutics, Inc. will post -0.46 EPS for the current year.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.